Hyglos GmbH is a leading German biotech company offering products for the capture, detection and decolonization of bacteria and bacterial components based on its advanced, proprietary phage-ligand technology. It is owned by Hyglos Invest GmbH and Institut Mérieux, investors coming from science and industry. Hyglos' core competency is to exploit the principles of bacteriophage biology for diagnostic, antimicrobial and research applications relating to:

• Endotoxin removal
• Endotoxin detection
• Endotoxin-free proteins and reagents
• Food and environmental microbiology
• Human Diagnostics
• Antimicrobials （e.g. MRSA）